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ABSTRACT 
 
Objective Changes in the occurrence of gastroesophageal reflux symptoms (GERS) 
in the population remain uncertain. This study aimed to determine the prevalence 
changes, the incidence, and the spontaneous loss of GERS. 
Design This population-based cohort study was conducted within the Nord-
Trøndelag health study (the HUNT study), a longitudinal series of population-based 
health surveys in Nord-Trøndelag County, Norway. The study base encompassed all 
adult residents in the county, and the participants reported the degree of GERS 
during the previous 12 months. The number of participants included were 58869 
(64% response rate) in 1995-1997 and 44997 (49%) in 2006-2009. Of these, 29610 
persons (61%) were prospectively followed up for an average of 11 years. 
Results Between 1995-1997 and 2006-2009, the prevalence of any, severe and at 
least weekly GERS increased by 30% (from 31.4% to 40.9%), 24% (from 5.4% to 
6.7%) and 47% (from 11.6% to 17.1%), respectively. The average annual incidence 
of any and severe GERS was 3.07% and 0.23%, respectively. In women, but not 
men, the incidence of GERS increased with increasing age. The average annual 
spontaneous loss (not due to antireflux medication) of any and severe GERS was 
2.32% and 1.22%, respectively. The spontaneous loss of GERS decreased with 
increasing age. 
Conclusion Between 1995-1997 and 2006-2009 the prevalence of GERS increased 
substantially. At least weekly GERS increased by 47%. The average annual 
incidence of severe GERS was 0.23%, and the corresponding spontaneous loss was 
1.22%. The incidence and spontaneous loss of GERS were influenced by sex and 
age. 
Occurrence of gastroesophageal reflux symptoms 
 
 
4 
 
 
What is already known about this subject? 
 The prevalence of at least weekly gastroesophageal reflux symptoms (GERS) 
among adults has been reported to be in the range of 10-20% in the Western 
world. 
 GERS are associated with a decreased health-related quality of life. 
 GERS are established risk factors of adenocarcinoma of the esophagus. 
 
What are the new findings? 
 The prevalence of at least weekly GERS increased by 47% (from 11.6% to 
17.1%) between 1995-1997 and 2006-2009. 
 The average annual incidence of severe GERS was 0.23%. In women, but not 
men, the incidence of GERS increased with increasing age. 
 The average annual spontaneous loss of severe GERS (not due to antireflux 
medication) was 1.22%. The spontaneous loss of GERS decreased with 
increasing age. 
 
How might it impact on clinical practice in the foreseeable future?  
 The increasing prevalence of GERS found in this study may call for a 
strengthened effort to investigate and treat this patient population, both due to 
the impact on health related quality of life and the increasing incidence of 
adenocarcinoma of the esophagus related to GERS. 
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MAIN TEXT 
 
INTRODUCTION 
Gastroesophageal reflux disease (GERD) is defined by its cardinal symptoms, 
heartburn and acid regurgitation, occurring at least weekly.1 2 Gastroesophageal 
reflux symptoms (GERS) are associated with a decreased health-related quality of 
life3 4 and an increased risk of adenocarcinoma of the esophagus,5 6 a disease with 
poor prognosis and rapidly rising incidence in Western countries.7-9 The prevalence 
of at least weekly GERS among adults has been reported to be in the range of 10-
20% in the Western world,10 11 with a higher prevalence in more recent studies.12 
However, the population-based changes in prevalence remain uncertain, and the few 
studies that have addressed the incidence of GERS suffer from small sample sizes, 
short follow-up time, or use of a selected population. In addition, GERS are not 
always persistent and the level of spontaneous loss of GERS, not due to antireflux 
medication, is unknown. The aim of this study was to provide valid data on the 
changes in prevalence, the incidence, and the spontaneous loss of GERS in an 
unselected Western population. 
Occurrence of gastroesophageal reflux symptoms 
 
 
6 
 
MATERIAL & METHODS 
Study population and design 
GERS were studied as part of the Nord-Trøndelag health study (the HUNT study), a 
longitudinal series of population-based health surveys conducted in the Norwegian 
county of Nord-Trøndelag. The county has a stable population that is representative 
of the Norwegian population at large.13 All adult residents in Nord-Trøndelag County 
who turned 20 years of age during the survey year were invited to participate. The 
first survey (HUNT 1), which was conducted in the mid 1980s, was not included in the 
present study because GERS data was not collected. However, the second survey 
(HUNT 2) conducted from August 1995 through June 1997 and the third survey 
(HUNT 3) conducted from October 2006 through June 2008 included assessment of 
GERS. Moreover, in 2009, a postal questionnaire study (Mini-Q) of the non-
participants in HUNT 3 was conducted, also including assessment of GERS and as 
such eligible in our study. The HUNT data base contains approximately 5500 health 
related variables, including variables on exposures, complaints, and diseases, 
collected through self-administered questionnaires, clinical measurements, and blood 
samples taken at the screening stations. 
 
Assessment of gastroesophageal reflux symptoms 
In HUNT 2 and HUNT 3/Mini-Q the participants were asked the following question 
through self-administrated questionnaires: “To what degree have you had heartburn 
or acid regurgitation during the previous 12 months?” and replied with one of three 
response alternatives: “no complaints”, “minor complaints”, or “severe complaints”. In 
the analyses, those who reported minor or severe complaints were included in the 
category “any GERS”, while those who reported severe complaints were included in 
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the category “severe GERS”. In HUNT 2, the GERS question was part of the initial 
questionnaire sent by mail along with the study invitation and returned at the 
screening station. In HUNT 3/Mini-Q, the GERS question was part of a second 
questionnaire given to the participants at the screening station (HUNT 3) or the 
questionnaire sent to the non-participants (Mini-Q). As frequency of GERS was not 
directly assessed in HUNT 2 and HUNT 3, the participants were asked to report both 
their degree and frequency of GERS in a validation study after HUNT 214 and in Mini-
Q. The following question was asked to assess the frequency of GERS: “If you have 
had heartburn or acid regurgitation during the previous 12 months, how often do you 
have complaints?” and replied with one of three response alternatives: “daily”, 
“weekly”, or “less frequently”. 
 
Assessment of antireflux medication 
Data on antireflux medication was collected from the HUNT questionnaires as well as 
from the Norwegian Prescription Database (NorPD). The NorPD is a Norwegian 
national health register, established in 2004, that contains data on all prescribed 
medication dispensed from all Norwegian pharmacies. Through the use of the unique 
national identity number assigned to all Norwegian residents, it was possible to link 
the HUNT study to the NorPD and gather information on the prescribed medication 
among the participants during HUNT 3. The prescription rules in Norway during the 
study period required a prescription from a physician for all proton pump inhibitors 
(PPIs) or H2-reseptor antagonists (H2RAs), except for small packages of low dose 
H2RAs. The information retrieved from the NorPD included dosage, package size, 
and number of packages for each single prescription. In addition, the participants in 
HUNT 3 reported their use of over the counter antireflux medication, i.e. small 
Occurrence of gastroesophageal reflux symptoms 
 
 
8 
 
packages of low dose H2RAs and antacids during the last month, with the response 
alternatives “never or rarely”, “1-3 times per week”, “4-6 times per week”, or “daily”. 
Thus, all antireflux medication in the study population during HUNT 3 should be 
accounted for. 
 
Statistical analyses 
Prevalence of GERS was calculated as the proportion of persons in HUNT 2 and 
HUNT 3/Mini-Q who reported any (minor or severe) GERS or severe GERS, 
respectively. The prevalence of individuals with at least weekly GERS in HUNT 2 and 
HUNT 3/Mini-Q was estimated through assessment of both degree and frequency of 
complaints reported by those participating in the HUNT 2 validation14 or in Mini-Q. 
The proportion of individuals with severe GERS and at least weekly GERS and the 
proportion of individuals with minor GERS and at least weekly GERS in the HUNT 2 
validation and in Mini-Q were calculated. These proportions were multiplied with the 
number of individuals with severe and minor GERS in HUNT 2 and HUNT 3, 
respectively, to assess at least weekly GERS.11 When calculating response rates, 
those who had deceased or were no longer resident in the county (non-eligible) were 
excluded from the denominator. The incidence of GERS was calculated from the 
proportion of those who reported no GERS in HUNT 2 and any or severe GERS in 
HUNT 3/Mini-Q (cumulative incidence), respectively. The loss of GERS was 
calculated from the proportion of those who reported any or severe GERS in HUNT 
2, respectively, but no GERS in HUNT 3/Mini-Q (cumulative loss). In the latter 
analysis, those using at least weekly antireflux medication in HUNT 3/Mini-Q were 
excluded to assess spontaneous loss of GERS only. The average annual cumulative 
incidence and spontaneous loss of GERS were calculated using the formula (exp 
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(cumulative proportion) – 1) / 11 years (average annual percentage change). In 
addition, 95% confidence intervals (CIs) for the proportions were calculated. The 
prevalence, incidence, and spontaneous loss of GERS were stratified by sex and age 
(<40, 40-49, 50-59, 60-69, and ≥70 years). Odds ratios (ORs) between the time 
points were estimated to statistically assess the changes in prevalence of GERS, and 
adjustments were made for sex and age by using the interaction term between sex 
and age groups as co-variable. Generalized estimating equations with exchangeable 
correlation structure were used to account for the repeated assessments of GERS 
among many of the participants. ORs were also estimated by logistic regression to 
assess differences in incidence and spontaneous loss of GERS by sex and age, 
using the interaction term as explanatory variable. The statistical analyses where 
performed with the software Stata/IC 11.1 for Windows by StataCorp LP. 
 
Ethical approval and informed consent 
The study was approved by the Regional Committee for Medical and Health 
Research Ethics, Central-Norway. All participants signed a written consent form 
when they participated in the HUNT study, which stated that the data collected could 
be linked with health registries and patient records for research purposes in future 
studies. 
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RESULTS 
Participants 
Degree of GERS was reported by 58869 individuals (64% response rate) in HUNT 2 
(1995-1997) and by 44997 individuals (49% response rate) in HUNT 3/Mini-Q (2006-
2009). The number of participants in HUNT 3 and Mini-Q were 37406 and 7591, 
respectively. These participants were included in the assessment of prevalence of 
GERS (Figure 1). In HUNT 2, the mean age was 48.5 years (standard deviation (SD) 
16.8 years; range 19-101 years) compared to 52.1 years (SD 16.0 years; range 19-
102 years) in HUNT 3/Mini-Q. The female response rate was 52% in HUNT 2 and 
55% in HUNT 3/Mini-Q, and 570 and 237 women reported to be pregnant, 
respectively. All analyses included pregnant women, as analyses excluding them 
made no differences in the results (data not shown). 
 
In the assessment of incidence and spontaneous loss of GERS between HUNT 2 
and HUNT 3/Mini-Q, the 29610 individuals who reported their degree of GERS at 
both occasions were included. This corresponds to a response rate of 61%, 
excluding the 10535 non-eligible participants who reported GERS in HUNT 2 but 
were deceased or no longer resident in the county at HUNT 3 (Figure 1). The mean 
age of this cohort was 57.3 years at follow-up (SD 13.1 years; range 29-100 years) 
and 54% were women. 
Occurrence of gastroesophageal reflux symptoms 
 
 
11 
 
Changes in prevalence of gastroesophageal reflux symptoms 
Between 1995-1997 and 2006-2009, the prevalence of any GERS increased by 30%, 
from 31.4% (95% CI 31.0-31.7%) to 40.9% (95% CI 40.4-41.3%), and the prevalence 
of severe GERS increased by 24%, from 5.4% (95% CI 5.2-5.6%) to 6.7% (95% CI 
6.4-6.9%). Adjusted for sex and age, the OR of any and severe GERS in 2006-2009 
compared with 1995-1997 was 1.46 (95% CI 1.43-1.49) and 1.20 (95% CI 1.15-1.26), 
respectively. For any GERS the prevalence increased for both sexes and all age 
groups, but for severe GERS the prevalence increased mainly among the middle 
aged (Table 1).
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Table 1: Prevalence of gastroesophageal reflux symptoms (GERS) in the HUNT study, stratified by degree of GERS, time point, sex, and age groups. 
  
 
Prevalence of any GERS* 
  
 
1995-1997 (HUNT 2) 
 
2006-2009 (HUNT 3/Mini-Q) 
 
Relative change† 
  
Total N=58869 
 
Total N=44997‡ 
 
Total 
  
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
 
18460 31.4 31.0-31.7 
 
18389 40.9 40.4-41.3 
 
30.3 
 
 
 
Women N=30608 
 
Men N=28261 
 
Women N=24550 
 
Men N=20440 
 
Women 
 
Men 
Age (years)§ Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
% 
 
All ages 
 
9104 29.7 29.2-30.3 
 
9356 33.1 32.6-33.7 
 
9526 38.8 38.2-39.4 
 
8860 43.3 42.7-44.0 
 
30.5 
 
30.9 
 
<40 
 
2528 23.9 23.1-24.7 
 
2695 29.4 28.5-30.3 
 
1886 28.3 27.2-29.4 
 
1516 34.5 33.1-35.9 
 
18.3 
 
17.5 
40-49 
 
1852 28.0 26.9-29.0 
 
2197 35.0 33.9-36.2 
 
1762 35.7 34.4-37.0 
 
1761 43.4 41.9-44.9 
 
27.7 
 
23.8 
50-59 
 
1635 31.9 30.6-33.1 
 
1823 36.0 34.7-37.3 
 
2157 42.1 40.7-43.4 
 
2258 46.7 45.3-48.1 
 
32.0 
 
29.8 
60-69 
 
1432 36.9 35.3-38.4 
 
1347 34.7 33.2-36.2 
 
2092 48.3 46.9-49.8 
 
1971 47.1 45.6-48.6 
 
31.2 
 
35.9 
≥70 
 
1657 37.6 36.2-39.1 
 
1294 33.5 32.0-35.0 
 
1629 46.6 44.9-48.2 
 
1354 45.6 43.8-47.4 
 
23.7 
 
36.2 
  
 
Prevalence of severe GERS* 
 
 
1995-1997 (HUNT 2) 
 
2006-2009 (HUNT 3/Mini-Q) 
 
Relative change† 
  
Total N=58869 
 
Total N=44997‡ 
 
Total 
  
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
 
3167 5.4 5.2-5.6 
 
2994 6.7 6.4-6.9 
 
23.7 
 
 
 
Women N=30608 
 
Men N=28261 
 
Women N=24550 
 
Men N=20440 
 
Women 
 
Men 
Age (years)§ Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
% 
 
All ages 
 
1603 5.2 5.0-5.5 
 
1564 5.5 5.3-5.8 
 
1629 6.6 6.3-6.9 
 
1364 6.7 6.3-7.0 
 
26.7 
 
20.6 
 
<40 
 
396 3.7 3.4-4.1 
 
436 4.8 4.3-5.2 
 
290 4.4 3.9-4.8 
 
223 5.1 4.4-5.7 
 
16.2 
 
6.8 
40-49 
 
286 4.3 3.8-4.8 
 
372 5.9 5.3-6.5 
 
289 5.9 5.2-6.5 
 
275 6.8 6.0-7.5 
 
35.6 
 
14.2 
50-59 
 
281 5.5 4.9-6.1 
 
312 6.2 5.5-6.8 
 
372 7.3 6.5-8.0 
 
390 8.1 7.3-8.8 
 
32.5 
 
31.0 
60-69 
 
299 7.7 6.9-8.5 
 
238 6.1 5.4-6.9 
 
385 8.9 8.0-9.7 
 
288 6.9 6.1-7.6 
 
15.6 
 
12.4 
≥70 
 
341 7.7 7.0-8.5 
 
206 5.3 4.6-6.0 
 
293 8.4 7.5-9.3 
 
188 6.3 5.5-7.2 
 
8.1 
 
18.8 
 
*Any GERS: minor or severe complaints with heartburn or acid regurgitation; Severe GERS: severe complaints with heartburn or acid regurgitation. 
†Relative change in prevalence = (prevalence HUNT 3/Mini-Q – prevalence HUNT 2) / prevalence HUNT. 
‡7 participants in HUNT 3/Mini-Q had missing information on sex. 
§Age at time of GERS assessment (HUNT 2 and HUNT 3/Mini-Q, respectively). 
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In Mini-Q, where the participants reported both their degree and frequency of GERS, 
98% of the participants with severe GERS had at least weekly symptoms or used at 
least weekly antireflux medication. The corresponding rate was 31% among 
participants with minor GERS. 
 
The prevalence of at least weekly GERS, estimated through assessment of data from 
the HUNT 2 validation and Mini-Q, increased by 47% from 11.6% (95% CI 11.4-
11.9%) to 17.1% (95% CI 16.7-17.4%). The prevalence of at least weekly GERS 
increased for both sexes and all age groups and most among the middle aged (Table 
2; Figure 2 online only). 
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Table 2: Prevalence of at least weekly gastroesophageal reflux symptoms (GERS) in the HUNT study, stratified by time point, sex, and age groups. 
  
 
Prevalence of at least weekly GERS* 
  
 
1995-1997 (HUNT 2) 
 
2006-2009 (HUNT 3/Mini-Q) 
 
Relative change† 
  
Total N=58869 
 
Total N=44997‡ 
 
Total 
  
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
 
6835 11.6 11.4-11.9 
 
7692 17.1 16.7-17.4 
 
47.2 
 
 
 
Women N=30608 
 
Men N=28261 
 
Women N=24550 
 
Men N=20440 
 
Women 
 
Men 
Age (years)§ Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
Number % 95% CI 
 
% 
 
% 
 
All ages 
 
3400 11.1 10.8-11.5 
 
3435 12.2 11.8-12.5 
 
4036 16.4 16.0-16.9 
 
3654 17.9 17.4-18.4 
 
48.0 
 
47.1 
 
<40 
 
910 8.6 8.1-9.2 
 
979 10.7 10.0-11.3 
 
778 11.7 10.9-12.5 
 
618 14.1 13.1-15.1 
 
35.6 
 
31.9 
40-49 
 
663 10.0 9.3-10.8 
 
810 12.9 12.1-13.8 
 
738 14.9 14.0-16.0 
 
729 18.0 16.8-19.2 
 
49.4 
 
39.0 
50-59 
 
606 11.8 10.9-12.7 
 
674 13.3 12.4-14.3 
 
916 17.9 16.8-18.9 
 
959 19.8 18.7-21.0 
 
51.3 
 
49.1 
60-69 
 
568 14.6 13.5-15.8 
 
504 13.0 11.9-14.1 
 
905 20.9 19.7-22.2 
 
803 19.2 18.0-20.4 
 
43.1 
 
47.9 
≥70 
 
653 14.8 13.8-15.9 
 
468 12.1 11.1-13.2 
 
700 20.0 18.7-21.4 
 
545 18.4 17.0-19.8 
 
34.9 
 
51.6 
 
*At least weekly GERS: at least weekly complaints with heartburn or acid regurgitation. 
†Relative change in prevalence = (prevalence HUNT 3/Mini-Q – prevalence HUNT 2) / prevalence HUNT 2. 
‡7 participants in HUNT 3/Mini-Q had missing information on sex. 
§Age at time of GERS assessment (HUNT 2 and HUNT 3/Mini-Q, respectively). 
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Incidence of gastroesophageal reflux symptoms 
During the average 11 years of follow-up from 1995-1997 to 2006-2009, the 
cumulative incidence of any GERS was 29.1% (95% CI 28.4-29.7%), which 
corresponded to an average annual incidence of 3.07% (95% CI 2.99-3.14%). 
Women younger than 40 years of age had the lowest incidence of any GERS. The 
incidence increased with increasing age for women, while it was stable with age for 
men. In older age groups there was no difference in the incidence of any GERS 
between the sexes (Table 3; Figure 3 online only). 
 
The cumulative incidence of severe GERS was 2.5% (95% CI 2.3-2.7%), which 
corresponded to an average annual incidence of 0.23% (95% CI 0.21-0.25%).There 
was a slightly increased incidence of severe GERS with increasing age for women, 
but it was stable with age for men. Women aged 60 to 69 years had the highest 
incidence of severe GERS (Table 3; Figure 3 online only). 
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Table 3: Cumulative incidence of gastroesophageal reflux symptoms (GERS) from 1995-1997 (HUNT 2) to 2006-2009  
(HUNT3/Mini-Q), stratified by degree of GERS, sex, and age groups.* 
              
 
 
Any GERS† 
              
 
Cumulative incidence 
 
OR and 95% CI‡ 
 
 
Total N=20311 
      
 
Number % 95% CI 
      
 
5904 29.1 28.4-29.7 
      
 
Women N=11394 
 
Men N=8917 
 
Women 
 
Men 
Age(years)§ Number % 95% CI 
 
Number % 95% CI 
 
OR 95% CI 
 
OR 95% CI 
All ages 3209 28.2 27.3-29.0 
 
2695 30.2 29.3-31.2 
      <40 283 20.5 18.3-22.6 
 
243 29.3 26.2-32.4 
 
1.00 Reference 
 
1.61 1.32-1.96 
40-49 704 25.9 24.2-27.5 
 
548 29.6 27.5-31.7 
 
1.36 1.16-1.59 
 
1.63 1.38-1.92 
50-59 900 29.1 27.5-30.7 
 
775 31.3 29.4-33.1 
 
1.59 1.37-1.85 
 
1.77 1.51-2.07 
60-69 823 33.3 31.5-35.2 
 
666 30.6 28.6-32.5 
 
1.94 1.66-2.27 
 
1.71 1.46-2.01 
≥70 499 28.9 26.8-31.1 
 
463 29.4 27.1-31.6 
 
1.58 1.34-1.87 
 
1.62 1.36-1.92 
              
 
 
Severe GERS† 
              
 
Cumulative incidence 
 
OR and 95% CI‡ 
 
 
Total N=20311 
      
 
Number % 95% CI 
      
 
510 2.5 2.3-2.7 
      
 
Women N=11394 
 
Men N=8917 
 
Women 
 
Men 
Age(years)§ Number % 95% CI 
 
Number % 95% CI 
 
OR 95% CI 
 
OR 95% CI 
All ages 319 2.8 2.5-3.1 
 
191 2.1 1.8-2.4 
      <40 31 2.2 1.5-3.0 
 
15 1.8 0.9-2.7 
 
1.00 Reference 
 
0.80 0.43-1.50 
40-49 66 2.4 1.8-3.0 
 
40 2.2 1.5-2.8 
 
1.08 0.70-1.67 
 
0.96 0.60-1.55 
50-59 95 3.1 2.5-3.7 
 
53 2.1 1.6-2.7 
 
1.38 0.92-2.08 
 
0.95 0.61-1.49 
60-69 85 3.4 2.7-4.2 
 
48 2.2 1.6-2.8 
 
1.55 1.03-2.36 
 
0.98 0.62-1.55 
≥70 42 2.4 1.7-3.2 
 
35 2.2 1.5-2.9 
 
1.09 0.68-1.74 
 
0.99 0.61-1.62 
 
*Cumulative incidence was calculated from no GERS in HUNT 2 to any or severe GERS in HUNT 3/Mini-Q, respectively. 
†Any GERS: minor or severe complaints with heartburn or acid regurgitation;  
Severe GERS: severe complaints with heartburn or acid regurgitation. 
‡Odds ratio (OR) and 95% confidence interval (CI) of incident GERS for each sex and age group. 
§Age at follow-up in HUNT 3/Mini-Q. 
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Spontaneous loss of gastroesophageal reflux symptoms 
The cumulative loss of any GERS during the study period was 22.7% (95% CI 21.9-
23.6%), when excluding the 286 participants (12%) using antireflux medication at 
least weekly. This corresponded to an average annual spontaneous loss of 2.32% 
(95% CI 2.23-2.42%). Women younger than 40 years of age had the highest 
spontaneous loss of any GERS. The spontaneous loss decreased with increasing 
age for both sexes, but this was more pronounced among women. There was no 
difference in spontaneous loss of any GERS between the sexes in older age groups 
(Table 4; Figure 4 online only). 
 
The cumulative loss of severe GERS was 12.6% (95% CI 10.9-14.2%), when 
excluding the 89 participants (31%) using antireflux medication at least weekly. This 
corresponded to an average annual spontaneous loss of 1.22% (95% CI 1.05-
1.40%). The spontaneous loss decreased with increasing age for both sexes, but this 
was particularly evident among women (Table 4; Figure 4 online only). 
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Table 4: Cumulative spontaneous loss of gastroesophageal reflux symptoms (GERS) from 1995-1997 (HUNT 2) to 2006-2009 
(HUNT3/Mini-Q), stratified by degree of GERS, sex and, age groups.* 
              
 
 
Any GERS† 
 
                          
 
Cumulative spontaneous loss 
 
OR and 95% CI‡ 
 
 
Total N=9299 
      
 
Number % 95% CI 
      
 
2112 22.7 21.9-23.6 
      
 
Women N=4686 
 
Men N=4613 
 
Women 
 
Men 
Age(years)§ Number % 95% CI 
 
Number % 95% CI 
 
OR 95% CI 
 
OR 95% CI 
All ages 1118 23.9 22.6-25.1 
 
994 21.5 20.4-22.7 
      <40 207 51.1 46.2-56.0 
 
74 27.9 22.5-33.3 
 
1.00 Reference 
 
0.37 0.27-0.52 
40-49 279 31.1 28.0-34.1 
 
209 25.0 22.1-27.9 
 
0.43 0.34-0.55 
 
0.32 0.25-0.41 
50-59 262 22.6 20.2-25.0 
 
287 21.3 19.1-23.5 
 
0.28 0.22-0.35 
 
0.26 0.20-0.33 
60-69 181 16.1 14.0-18.3 
 
229 19.0 16.7-21.2 
 
0.18 0.14-0.24 
 
0.22 0.18-0.29 
≥70 189 17.2 14.9-19.4 
 
195 20.4 17.8-22.9 
 
0.20 0.15-0.25 
 
0.24 0.19-0.31 
              
 
 
Severe GERS† 
 
              
 
          
 
Cumulative spontaneous loss 
 
OR and 95% CI‡ 
 
 
Total N=1553 
      
 
Number % 95% CI 
      
 
195 12.6 10.9-14.2 
      
 
Women N=798 
 
Men N=755 
 
Women 
 
Men 
Age(years)§ Number % 95% CI 
 
Number % 95% CI 
 
OR 95% CI 
 
OR 95% CI 
All ages 93 11.7 9.4-13.9 
 
102 13.5 11.1-16.0 
      <40 25 37.3 25.6-49.0 
 
9 26.5 11.4-41.5 
 
1.00 Reference 
 
0.60 0.24-1.50 
40-49 23 17.6 11.0-24.1 
 
20 15.6 9.3-21.9 
 
0.36 0.18-0.70 
 
0.31 0.16-0.62 
50-59 19 10.4 6.0-14.9 
 
32 14.7 10.0-19.5 
 
0.20 0.10-0.39 
 
0.29 0.16-0.54 
60-69 13 7.0 3.3-10.6 
 
22 10.6 6.4-14.8 
 
0.13 0.06-0.27 
 
0.20 0.10-0.39 
≥70 13 5.6 2.6-8.6 
 
19 11.3 6.5-16.1 
 
0.10 0.05-0.21 
 
0.21 0.11-0.43 
 
*Cumulative spontaneous loss was calculated from any or severe GERS in HUNT 2, respectively, to no GERS in HUNT 3/Mini-Q, 
excluding those using at least weekly antireflux medication. 
†Any GERS: minor or severe complaints with heartburn or acid regurgitation;  
Severe GERS: severe complaints with heartburn or acid regurgitation. 
‡Odds ratio (OR) and 95% confidence interval (CI) of losing GERS for each sex and age group. 
§Age at follow-up in HUNT 3/Mini-Q. 
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Non-participant study 
In Mini-Q and HUNT 3, respectively, 29.9% and 43.1% reported any GERS; 4.3% 
and 7.1% reported severe GERS; and 5.7% and 8.2% used at least weekly antireflux 
medication. These differences were retained also after stratification by sex and age 
(data not shown). Distributions of key variables associated with GERS were also 
assessed. In Mini-Q and HUNT 3, respectively, 49% and 56% were women; the 
mean age was 45.9 and 53.4 years; the mean body mass index (BMI) was 26.1 and 
27.2 kg/m2; there were no differences in the proportions of none or daily cigarette 
smokers; 34% and 38% drank at least weekly alcohol; and 69% and 79% reported at 
least weekly physical exercise. 
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DISCUSSION 
The present study found a substantial increase in the prevalence of GERS during the 
last decade. The absolute number of individuals with new GERS exceeded the 
number who lost GERS during the study period. Age was an important risk factor for 
the incidence of GERS among women, but for men the incidence was stable 
irrespective of age. GERS was frequently lost, especially among young women, but 
seemed to be more stable with increasing age. Analyses excluding pregnant women 
made no differences in the results. The use of regular antireflux medication could 
only explain the loss of GERS in a minority of participants.  
 
There are a few methodological issues to be discussed. Major strengths were i) the 
population-based design, which reduced the risk of selection bias compared to 
studies of individuals consulting physicians or in other health care settings; ii) the 
large study population, which reduced the risk of chance findings and made 
subgroup analyses possible; and iii) the ability to account for the use of antireflux 
medication among participants with loss of GERS. Limitations of the study were i) the 
drop in participation rate from HUNT 2 to HUNT 3, making differences in selection 
bias between the surveys possible; and ii) the long time interval (11 years) between 
the surveys, which prevented evaluation of additional fluctuations in GERS during the 
study period. Thus, the analysis of incident GERS may also have included recurrent 
symptoms and not only genuinely new cases, and loss of GERS may not necessarily 
mean a true recovery, but rather a temporary relief of symptoms. The probability of 
fluctuating symptoms was, however, most likely reduced by the 12 months time 
period the individuals were asked to consider when reporting GERS. Selection bias is 
a major concern in all population-based studies including the present study. 
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However, compared to other population-based cohort studies of this magnitude the 
overall response rate is high. In addition, the purpose of the HUNT study was to 
perform an extensive investigation of common diseases and exposures using a wide 
range of health related variables. Thus, non-participation due to GERS is highly 
unlikely as there were only two questions related to GERS in the HUNT study. In 
Mini-Q the prevalence of both any and severe GERS and the use of antireflux 
medication was lower than in HUNT 3, also after stratification by sex and age. The 
higher prevalence of GERS in Mini-Q may indicate a selection of individuals with 
more complaints in the study population than in the target population and possibly an 
overestimation of the occurrence of GERS. However, this bias is reduced with the 
inclusion of the participants in Mini-Q in the study population. The lower prevalence 
of GERS in Mini-Q may in part be explained by the lower BMI of this population. 
Finally, the definition of GERD is arbitrary, but according to present guidelines it is 
based mainly on the frequency of GERS,2 which is in line with the present study. Our 
previous validation study (HUNT 2 validation) showed that 95% of the participants 
with severe GERS had at least weekly symptoms or used at least weekly antireflux 
medication.14 The corresponding proportion of 98% in Mini-Q confirmed this result 
and implies reliability of the GERS assessment in the HUNT study. 
 
Previous research on the population-based prevalence of GERS is heterogeneous 
and comparisons between prevalence studies are inherently difficult since GERS are 
subjective and the definition of GERD varies between studies. In addition, the sample 
size of previous studies is generally small. A few studies have assessed the change 
in prevalence of GERS by investigating the same source population at a minimum of 
two time points. Two US studies, conducted in the same source population in 1980 
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and in 1988-1991, found an increase in the prevalence of at least weekly heartburn 
from 13.2% (n=835; aged 30-64 years) to 17.8% (n=1511; aged 25-74 years), but no 
change in at least weekly acid regurgitation (6.5% and 6.3%, respectively).15 16 In a 
Swedish study, the prevalence of any GERS increased from 20-21% in 1986 (n=337; 
aged 20-79 years) to 22-25% at follow-up 10 years later (n=197).17 18 In another 
Swedish population, the prevalence of any GERS increased from 18.9% in 1988 
(n=1156; aged 20-79 years) to 19.4% at follow-up in 1995 (n=877).19 In a recent 
Danish study from 1998-1999, the prevalence of at least mild GERS at baseline was 
22% (n=6781; aged 40-65 years) and was reported to be stable at follow-up 5 years 
later (n=5578).20 Except for this last study, there was an increasing prevalence of 
GERS over time in all populations, but this increase was not as pronounced as in the 
present study. The increasing prevalence of GERS is alarming since it most likely will 
contribute to the increasing incidence of adenocarcinoma of the esophagus in the 
Western population.5 6 
 
Only a few population-based studies have assessed the prevalence of GERS in the 
same cohort during at least two time points and addressed incidence or loss of 
GERS. Generally these studies have a small sample size, a short follow-up time, or a 
selected population. A Danish study with baseline in 1982-1984 and follow-up 
assessment in 1987-1988 (n=2987; aged 30-60 years at baseline) reported an 
annual incidence of any GERS of 13-19% and an annual incidence of frequent GERS 
of 1-3%.21 A Swedish study with baseline in 1988 and 1 year follow-up (n=1059; 
aged 20-79 years at baseline) reported an annual incidence of predominant GERS of 
0.05% and an annual incidence of GERS with other concurrent gastrointestinal 
symptoms of 0.75%.22 A US study from 1988-1991 with 12-20 months follow-up 
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(n=690; aged 30-64 years at baseline) reported a cumulative onset rate of heartburn 
several times a week or daily of 2.7%, corresponding to average annual onset rates 
of 1.6-2.7%.23 In another Swedish population with baseline assessment in 1986 and 
follow-up 10 years later (n=197; aged 20-79 years at baseline), the annual incidence 
of any GERS was 1.2-1.8%.18 In the most recent study from Denmark with baseline 
in 1998-1999 and follow-up assessment 5 years later (n=5578; aged 40-65 years at 
baseline), an annual incidence of at least mild GERS of 2.2% was reported.20 Except 
for the first Danish study, these incidence figures comply with the results of our study, 
and over the last two decades the incidence seems to been quite stable among these 
populations. However, in our study we were able to show an effect of age on the 
incidence of GERS among women. 
 
The first Danish study reported cumulative loss of any GERS of 27-37%, 
corresponding to average annual loss of 6.2-9.0%, and cumulative loss of frequent 
GERS of 59-77%, corresponding to average annual loss of 16.1-23.2%.21 The US 
study reported cumulative loss of heartburn several times a week or daily of 47.8%, 
corresponding to average annual loss of 36.9-61.3%.23 The second Swedish study 
reported annual loss of any GERS of 1.1-1.3%,18 and the most recent Danish study 
reported annual loss of at least mild GERS of 8.6%.20 Except for the second Swedish 
study, these figures on loss of GERS deviate from our results, but our large sample 
size, long follow-up time, and ability to adjust for antireflux medication argue for 
validity. In addition, we showed a considerable effect of age on the spontaneous loss 
of GERS.  
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There might be several reasons why the prevalence of GERS has increased during 
the last decade. The body weight has increased in the population, and high BMI is an 
established risk factor of GERS. The increasing age of the cohort may contribute, but 
the prevalence increased also after adjustment for age. However, it is interesting that 
the incidence and spontaneous loss of GERS were influenced by age, particularly for 
women. Postmenopausal hormone replacement therapy seems to be a risk factor of 
GERS and may to some extent contribute to this pattern for women.14 24 The 
substantial loss of GERS, not due to antireflux medication, found in the present 
study, is partly conflicting with the presumed chronic character of GERS and the 
large use of regular antireflux medication in this population. Besides antireflux 
medication, there are few data on the prevention and treatment of GERS in a 
population-based setting. These issues will be addressed in depth in future studies 
using the HUNT study. 
 
CONCLUSION 
In this large prospective population-based cohort study there was a considerable 
increase in the prevalence of GERS between 1995-1997 and 2006-2009, and the 
prevalence of at least weekly GERS increased by 47%. The average annual 
cumulative incidence of severe GERS was 0.23%, and the average annual 
spontaneous loss of severe GERS (not due to antireflux medication) was 1.22%. The 
incidence and spontaneous loss of GERS differed between the sexes and with age. 
 
FIGURE LEGENDS 
(Figure1.pdf) 
 
Figure 1: Flowchart of participants reporting gastroesophageal reflux symptoms (GERS) in HUNT 2 (1995-1997) and HUNT 
3/Mini-Q (2006-2009) with number (N) of individuals at each stage and response rates (%). Response rates were calculated 
from those eligible, excluding those deceased or no longer resident in the county (non-eligible). 
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FIGURE LEGENDS ONLINE ONLY MATERIAL 
(Figure2.pdf) 
 
Figure 2: Prevalence of at least weekly gastroesophageal reflux symptoms for each sex and age groups in 1995-1997 (HUNT 
2) and 2006-2009 (HUNT 3/Mini-Q). Vertical lines represent 95% confidence intervals. 
 
(Figure3.pdf) 
 
Figure 3: Cumulative incidence of any and severe gastroesophageal reflux symptoms for each sex and age groups (age at 
follow-up) between 1995-1997 (HUNT 2) and 2006-2009 (HUNT 3/Mini-Q). Vertical lines represent 95% confidence intervals. 
 
(Figure4.pdf) 
 
Figure 4: Cumulative spontaneous loss of any and severe gastroesophageal reflux symptoms for each sex and age groups 
(age at follow-up) between 1995-1997 (HUNT 2) and 2006-2009 (HUNT 3/Mini-Q). Vertical lines represent 95% confidence 
intervals. 
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